Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 17, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
On April 16, 2007, administrators notified the company of an increase in interests in Ordinary Share ADRs for specific individuals following the reinvestment of dividends paid on April 12, 2007. The transaction price was $56.84 per ADR. The specific increases were:
- Dr JP Garnier: 1,700.88 ADRs
- Mr D J Phelan: 328.05 ADRs
- Mr D M Stout: 131.12 ADRs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of ADRs held by the named directors post-transaction.
- Confirm the dividend reinvestment plan terms applicable to the SmithKline Beecham Mid-Term Incentive Plan.
- Check subsequent filings for any further changes in director holdings.